Clarivate Plc logo

Clarivate Plc (CLVT)

Market Closed
1 Sep, 20:00
NYSE NYSE
$
2. 04
-0.01
-0.4878%
$
1.29B Market Cap
36.92 P/E Ratio
- Div Yield
2.83M Volume
0.8 Eps
$ 2.05
Previous Close
Add Transaction
Day Range
2 2.17
Year Range
1.66 4.54
Want to track CLVT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Clarivate Q2 Earnings Call Highlights

Clarivate Q2 Earnings Call Highlights

Clarivate NYSE: CLVT said during its earnings call that it expects organic recurring revenue and annualized contract value growth to improve in the second half of the year, citing renewal visibility, product momentum and a growing pipeline of AI-enabled offerings.

Marketbeat | 1 month ago
Clarivate (CLVT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Clarivate (CLVT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Clarivate (CLVT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 1 month ago
Clarivate PLC (CLVT) Q2 Earnings and Revenues Beat Estimates

Clarivate PLC (CLVT) Q2 Earnings and Revenues Beat Estimates

Clarivate PLC (CLVT) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.18 per share a year ago.

Zacks | 1 month ago
Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business

Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business

Clarivate NYSE: CLVT said it has reached an agreement to sell substantially all of its Life Sciences & Healthcare segment to Altaris, an investment firm focused on the healthcare industry, in a transaction valued at $600 million.

Marketbeat | 1 month ago
Clarivate: Business Showed Signs Of Stabilization, But It Is Not Enough

Clarivate: Business Showed Signs Of Stabilization, But It Is Not Enough

Clarivate delivered improved Q1 2026 results, with organic growth turning positive at 0.6% and margin expansion, but reported revenue still declined year over year. Segment trends stabilized, notably with Academia & Government and Life Sciences & Healthcare returning to growth, though IPPG remained a drag at -1.3% organic growth. AI-driven product enhancements and the Value Creation Plan could accelerate organic growth, but sustained improvement is needed before a re-rating is justified.

Seekingalpha | 3 months ago
Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript

Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript

Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript

Seekingalpha | 4 months ago
Compared to Estimates, Clarivate (CLVT) Q1 Earnings: A Look at Key Metrics

Compared to Estimates, Clarivate (CLVT) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Clarivate (CLVT) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 4 months ago
Clarivate PLC (CLVT) Tops Q1 Earnings and Revenue Estimates

Clarivate PLC (CLVT) Tops Q1 Earnings and Revenue Estimates

Clarivate PLC (CLVT) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.14 per share a year ago.

Zacks | 4 months ago
Clarivate: The Data Intelligence Company Flying Under the Radar

Clarivate: The Data Intelligence Company Flying Under the Radar

Most investors have never heard of Clarivate. The company operates largely outside mainstream investor attention.

247wallst | 5 months ago
Clarivate Plc (CLVT) Presents at Wolfe Research FinTech Forum Transcript

Clarivate Plc (CLVT) Presents at Wolfe Research FinTech Forum Transcript

Clarivate Plc (CLVT) Presents at Wolfe Research FinTech Forum Transcript

Seekingalpha | 5 months ago
Clarivate: Deleveraging And FCF Growth Support A Re-Rating

Clarivate: Deleveraging And FCF Growth Support A Re-Rating

Clarivate is executing a turnaround, with management focusing on debt reduction, divestitures, and share buybacks after years of value-destructive acquisitions. Q4 and FY25 results marked the first time CLVT met initial full-year guidance since 2019, with sequential organic ACV growth and 88% recurring revenue. 2026 guidance projects organic ACV growth of 2–3%, adjusted EBITDA margin near 43%, and FCF around $400M, despite headline revenue decline from low-margin business exits.

Seekingalpha | 5 months ago
Clarivate: A Tough Operating Backdrop Ahead

Clarivate: A Tough Operating Backdrop Ahead

Clarivate (CLVT) remains a hold as core organic growth continues to deteriorate, with no evidence of recovery despite multiple compression. AI-driven shifts in user behavior and low barriers to entry are intensifying competitive threats, raising doubts about CLVT's long-term growth prospects. Strategic positives include the planned sale of the underperforming LSH segment and improved recurring revenue mix, but these do not offset weak fundamentals.

Seekingalpha | 5 months ago
Loading...
Load More